U2AF1 and acute myeloid leukemia: By contrast, U2AF1 mutations co-occur with RAS mutations, suggesting that the resistance and early relapse of U2AF1-mutated AML after azacitidine–venetoclax may be the result of RAS co-mutation rather than of U2AF1 itself [93,100].